Hong Xie

Also affiliated with PA Consulting Group

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma”.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

UNC Libraries(2020)10.17615/tmgg-w910

N/A

0DataRank · unranked

0 citations

Suzanne Lentzsch, Pieter Sonneveld, Sonja Zweegman, Hong Xie, Xiang Qin +13 more

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

UNC Libraries(2020)10.17615/tpk1-js83

N/A

0DataRank · unranked

0 citations

Deborah J. Kuhn, Robert Z. Orlowski, Valeria Magarotto, Mark Cornfeld, Michael Wang +8 more

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.02.010

N/A

0DataRank · unranked

58 citations

Michael T. Schweizer, Kim N., Rahul Aggarwal, Neeraj Agarwal, James L. Gulley +9 more